Biodexa Pharmaceuticals plc has announced the enrollment of its first patient in a phase 2a clinical trial for Tolimidone, a drug being investigated for the treatment of type 1 diabetes. The trial, conducted in collaboration with the University of Alberta, aims to confirm dosing and evaluate the drug's impact on insulin production and blood glucose levels over a three-month period. The study, approved by Health Canada, will initially involve 12 patients across three dose groups, with potential for expansion. Results from this trial have not yet been presented and are anticipated in the future. Biodexa aims to develop Tolimidone as a first-in-class blood glucose modulating agent, potentially offering a new oral treatment option for type 1 diabetes patients.